Obesity and Type 2 Diabetes Mellitus

1. Auflage 2011
ISBN: 978-0-19-974021-5
Verlag: Oxford University Press

Buch, Englisch, 96 Seiten, Format (B × H): 127 mm x 203 mm, Gewicht: 154 g

Reihe: Oxford American Endocrinology Library

Includes easy-reference prescription dosage charts perfect for point-of-care reference
Includes concise yet comprehensive information on macrovascular risk reduction via therapeutic lifestyle change as well as pharmacotherapeutic treatment of dyslipidemia and hypertension
Uniquely compact and affordable

With the advent of the worldwide obesity epidemic, a concurrent rise has occurred in the prevalence of type 2 diabetes mellitus and metabolic syndrome. Type 2 diabetes mellitus is affecting younger individuals-the disease is no longer exclusive to adulthood. Diabetic micro- and macrovascular complications are also occurring at an earlier age, leading to increasing demands and costs on the healthcare system. In addition, the morbidity, disability and premature death caused by diabetic complications create a huge burden to families, employers and society at large. Thankfully, there has been a tremendous growth in new therapeutic classes of medications to help manage type 2 diabetes mellitus. These agents target many of the pathophysiologic defects of the disease with fewer side effects than the older agents. Newer insulin formulations have more predictable kinetics so patients can achieve better glycemic control with less risk of hypoglycemia and weight gain. Insulin delivery devices have also improved to include higher quality insulin pens, finer and shorter pen needles, and more technologically advanced insulin pumps.

As part of the Oxford American Endocrinology Library series, this handbook reviews the epidemiology and pathophysiology of obesity and type 2 diabetes mellitus. The content covers micro- and macrovascular diabetic complications, the array of glucose regulating therapies, treatment algorithms targeting the pathophysiologic defects of type 2 diabetes mellitus as well as strategies for macrovascular risk reduction via therapeutic lifestyle change (diet, exercise, smoking cessation), pharmacotherapeutic treatment of dyslipidemia and hypertension, bariatric surgery and subcutaneous insulin infusion therapy, among other topics. Because of the concise yet comprehensive nature of the handbook, this volume is an excellent point-of-care reference for the clinician who regulary treats obese and diabetic patients.

Zielgruppe

General healthcare practitioners, internists and primary care providers

Autoren/Hrsg.

Sheehan, John P

Ulchaker, Margaret M

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Diabetologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Endokrinologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Stoffwechselstörungen

Inhaltsverzeichnis

Preface
Introduction
1. Epidemiology
Populations at Risk for T2DM
Health and Socioeconomic Impact
2. Diagnostic Criteria
3. Pathophysiology
4. Management of T2DM
5. Management of Obesity: Implications for T2DM
6. Microvascular and Macrovascular Complications of T2DM: Prevention and Treatment
7. Common Co-morbidities of T2DM and Obesity
8. Special Situations and T2DM
9. Prevention of T2DM
Conclusion

Über Autor(innen)

John P. Sheehan, MD, FACE, FACN, is Medical Director at North Coast Institute of Diabetes and Endocrinology, Inc. and Associate Clinical Professor of Medicine at Case Western Reserve University in Cleveland, Ohio.

Margaret M. Ulchaker, MSN, RN, CDE, CNP, NP-C, BC-ADM is Endocrine Nurse Practitioner at North Coast Institute of Diabetes and Endocrinology, Inc. And Clinical Instructor at Frances Payne Bolton School of Nursing, Case Western Reserve University in Cleveland, Ohio.